Built on its proprietary ImmTAX platform, the company has a diverse pipeline of bispecific therapies, with the platform modular allowing regulation of the immune system to tackle cancer (ImmTAC) or infectious diseases (ImmTAV), and downregulate it to address autoimmune conditions (ImmTAAI). Immunocore's strategic commercialization of its flagship KIMMTRAK with launches in 30 countries including key markets like the United States, Germany, and France, reflects plans for geographic expansion and patient reach enhancement.
Cyborg Score Rationale
In 2024, Immunocore Holdings's revenue was $310.20 million, an increase of 24.37% compared to the previous year's $249.43 million. While KIMMTRAK sales have supported the company, they have not been enough to achieve profitability. According to 11 analysts, the average rating for IMCR stock is "Buy."
Top Insights
KIMMTRAK has been approved in 39 countries for the treatment of unresectable or metastatic uveal melanoma (mUM).
Key pipeline assets include IMC-R117C in Phase 1/2 for advanced solid tumors, IMC-M113V in Phase 1 for potential HIV functional cure, and IMC-I109V in Phase 1 for potential HBV functional cure.
Immunocore has reported net losses each year since inception with an accumulated deficit of $831.3 million as of December 31, 2025.
The company has 524 employees with a significant portion engaged in R&D activities.
Named Competitors
CAR-T therapy programs — CAR-T cell therapy for oncology
TCR therapy programs — T-cell receptor immunotherapy development
Checkpoint inhibitors and melanoma therapies — Traditional oncology immunotherapies
Recent Developments
(February 2026) Filed 10-K with detailed financial statements and strategic direction
(Q3 2025) KIMMTRAK net revenues of $103.7 million, growing 29% year-over-year
(January 2026) Announced 2026 strategic priorities at J.P. Morgan Healthcare Conference
Open the full interactive Immunocore Holdings plc report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.